Brief: Celon Pharma Announces Positive Bioequivalence Results For Semaglutide (Reduzek)
20/08/2026 10:39
BRIEF-Celon Pharma Announces Positive Bioequivalence Results For Semaglutide (Reduzek) Aug 20 (Reuters) - Celon Pharma SA CLNP.WA:
ANNOUNCES POSITIVE BIOEQUIVALENCE RESULTS FOR SEMAGLUTIDE (REDUZEK)
SEMAGLUTIDE CELON 0.5 MG (REDUZEK) BIOEQUIVALENT TO WEGOVY 0.5 MG AND OZEMPIC 0.5 MG
STUDY CONFIRMS BIOEQUIVALENCE OF REDUZEK TO WEGOVY AND OZEMPIC
POSITIVE RESULTS ALLOW EXTENSION OF BIOEQUIVALENCE TO OTHER DOSES
Source text: ID:nEM29PSsNa
Further company coverage: CLNP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Celon Pharma SA
See all newsBrief: Celon Pharma Projects Recommended For About 29.9 Mln Zlotys Funding By Poland's Medical Research Agency
Brief: Celon Pharma Files Marketing Authorization Applications In EU For Semaglutide Drug Injection Solution
Brief: Celon Pharma Q2 Net Loss At 30.6 Million Zlotys
Brief: Celon Pharma Gets Positive Opinion Confirming Reduzek Compliance With Safety Requirements
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump